doi:10.1186/s12931-022-02092-9engMarín-Oto, M.Sanz-Rubio, D.Santamaría-Martos, F.Benitez, I.Simon, A. L.Forner, M.Cubero, P.Gil, A.Sánchez de la Torre, M.Barbe, F.Marín, J. M.Soluble RAGE in COPD, with or without coexisting obstructive sleep apnoeaART-2022-129616Background: Hypoxia can reduce the levels of soluble receptor for advanced glycation end-products (sRAGE), a new anti-inflammatory biomarker of COPD. We assessed sRAGE in patients with hypoxia-related diseases such as COPD, OSA and OSA-COPD overlap. Methods: Plasma levels of sRAGE were measured in 317 subjects at baseline (57 heathy nonsmokers HNS], 84 healthy smokers HS], 79 OSA, 62 COPD and 35 OSA-COPD overlap patients) and in 294 subjects after one year of follow-up (50 HNS, 74 HS, 77 OSA, 60 COPD and 33 overlap). Results: After adjusting for age, sex, smoking status and body mass index, sRAGE levels showed a reduction in OSA (- 12.5%, p = 0.005), COPD (- 14.8%, p < 0.001) and OSA-COPD overlap (- 12.3%, p = 0.02) compared with HNS. There were no differences when comparing sRAGE plasma levels between overlap patients and those with OSA or COPD alone. At follow-up, sRAGE levels did not change significantly in healthy subjects, COPD and OSA or OSA-COPD overlap nontreated with continuous positive airway pressure (CPAP). Moreover, in patients with OSA and OSA-COPD overlap who were treated with CPAP, sRAGE increased significantly. Conclusions: The levels of sRAGE are reduced in COPD and OSA. Treatment with CPAP appears to improve sRAGE levels in patients with OSA who also had COPD.2022http://zaguan.unizar.es/record/11821810.1186/s12931-022-02092-9http://zaguan.unizar.es/record/118218oai:zaguan.unizar.es:118218info:eu-repo/grantAgreement/ES/ISCIII-FEDER-FIS/PI18-01524info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI12-02175info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI15-01940Respiratory Research 23 (2022), 163 [9 pp.]byhttps://creativecommons.org/licenses/by/4.0/deed.esinfo:eu-repo/semantics/openAccess